GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Theralase Technologies (TSXV:TLT) Cash, Cash Equivalents, Marketable Securities : C$0.13 Mil (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Cash, Cash Equivalents, Marketable Securities?

Theralase Technologies's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 (C$0.33 Mil) to Dec. 2024 (C$0.27 Mil) but then stayed the same from Dec. 2024 (C$0.27 Mil) to Mar. 2025 (C$0.13 Mil).

Theralase Technologies's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (C$1.51 Mil) to Dec. 2023 (C$0.04 Mil) but then increased from Dec. 2023 (C$0.04 Mil) to Dec. 2024 (C$0.27 Mil).


Theralase Technologies Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Theralase Technologies's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Cash, Cash Equivalents, Marketable Securities Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.88 3.69 1.51 0.04 0.27

Theralase Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.43 0.33 0.27 0.13

Theralase Technologies Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Theralase Technologies  (TSXV:TLT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Theralase Technologies Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Industry
Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 08-15-2022

Top 5 2nd Quarter Trades of SYNOVUS FINANCIAL CORP

By GuruFocus Research GuruFocus Editor 08-11-2022

Top 5 4th Quarter Trades of Starfox Financial Services, LLC

By GuruFocus Research GuruFocus Editor 02-08-2023

Louis Moore Bacon Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-14-2022

Top 5 3rd Quarter Trades of Eqis Capital Management, Inc.

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 3rd Quarter Trades of Financial Sense Advisors, Inc.

By GuruFocus Research GuruFocus Editor 10-13-2022

Top 5 3rd Quarter Trades of PINNACLE FINANCIAL PARTNERS INC

By GuruFocus Research GuruFocus Editor 10-31-2022

Top 5 4th Quarter Trades of Financial Sense Advisors, Inc.

By GuruFocus Research GuruFocus Editor 02-07-2023